Conference call on Interim Report
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January – March 2017. The presentation will be held in English.
Time: Tuesd ay , April 25, 2017 at 2.00 p.m. CET
Registration can preferably be done in advance under the following link:
or shortly before time of the conference starts on:
Sweden dial in number: +46 (0)8 5059 6306
USA dial in number: +1 718 873 9077
International dial in number: +44 (0)203 139 4830
Conference name: XVIVO Perfusion, conference ID: 60628234#
Participants from XVIVO Perfusion:
Magnus Nilsson, CEO
Christoffer Rosenblad, CFO
The press release for XVIVO Perfusion’s interim report January – March 2017 will be released before the conference call April 25, 2017.
Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com/corporate/.
April 19, 2017
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, email@example.com
Magnus Nilsson, CEO, +46 31-788 21 50, e-post: magnus.nilsson@xvivoperfusion
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: firstname.lastname@example.org. Website: www.xvivoperfusion.com